Dovitinib as second-line therapy in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or non-mutated advanced and/or metastatic endometrial cancer (EC): A single-arm, multicenter, phase II study. Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Konecny, Gottfried E., Finkler, Neil, Garcia, Agustin, Raspagliesi, Francesco, Lopez, Carolina Muriel, McCollum, Michael, Rubio, M. Jesus, Squires, Matthew, Pirotta, Nicoletta, Upalawanna, Allison, Yovine, Alejandro Javier, Rocconi, Rodney Paul

Publication Date

  • May 20, 2013

webpage

published in

category

volume

  • 31

issue

  • 15

WoS Citations

  • 0

WoS References

  • 0